**Name of Journal: *World Journal of Orthopedics***

**ESPS Manuscript NO: 31743**

**Manuscript Type: Systematic Reviews**

**Dementia and osteoporosis in a geriatric population: Is there a common link?**

Downey CL *et al.* Dementia and osteoporosis in a geriatric population

**Candice L Downey, Adam Young, Emily F Burton, Simon M Graham, Robert J Macfarlane, Eva-Maria Tsapakis, Eleftherios Tsiridis**

**Candice L Downey, Emily F Burton,** University of Leeds, School of Medicine, Leeds LS2 9NL, United Kingdom

**Adam Young,** Department of Anaesthetics, Pinderfields Hospital, Wakefield WF1 4DG, United Kingdom

**Simon M Graham, Robert J Macfarlane,** Department of Trauma and Orthopaedics, the Royal Liverpool University Hospital, Liverpool L7 8XP, United Kingdom

**Eva-Maria Tsapakis, Eleftherios Tsiridis,** Academic Department of Orthopaedics and Trauma, Aristotle University Medical School, 54124 Thessalonika, Greece

**Author contributions:** Downey CL and Young A contributed equally to this work; Tsiridis EM and Downey CLdesigned the research; Downey CL, Young A and Burton EF performed the research and wrote the paper; Graham SM, Macfarlane RJ and Tsiridis EM provided significant contributions in drafting the paper and revising it critically for important intellectual content; Tsapakis EM provided expert review.

**Conflict-of-interest statement:** The authors confirm that there are no potential conflicts of interest. There is no financial support to declare.

**Data sharing statement:** None.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Correspondence to: Simon M Graham, MBChB, MRCS,** Department of Trauma and Orthopaedics, the Royal Liverpool University Hospital, Prescot St, Liverpool L7 8XP, United Kingdom. simonmatthewgraham@doctors.org.uk

**Telephone:** +44-151-7062000

Fax: +44-151-7065806

**Received:** December 5, 2016

**Peer-review started:** December 6, 2016

**First decision:** January 16, 2017

**Revised:** February 8, 2017

**Accepted:** February 28, 2017

**Article in press:**

**Published online:**

**Abstract**

***AIM***

To determine the existence of a common pathological link between dementia and osteoporosis through reviewing the current evidence base.

***METHODS***

This paper reviews the current literature on osteoporosis and dementia in order to ascertain evidence of a common predisposing aetiology. A literature search of Ovid MEDLINE (1950 to June 2016) was conducted. The keywords “osteoporosis”, “osteoporotic fracture”, “dementia” and “Alzheimer’s disease” (AD) were used to determine the theoretical links with the most significant evidence base behind them. The key links were found to be vitamins D and K, calcium, thyroid disease, statins, alcohol and sex steroids. These subjects were then searched in combination with the previous terms and the resulting papers manually examined. Theoretical, *in vitro* and *in vivo* research were all used to inform this review which focuses on the most well developed theoretical common causes for dementia (predominantly Alzheimer’s type) and osteoporosis.

***RESULTS***

Dementia and osteoporosis are multifaceted disease processes with similar epidemiology and a marked increase in prevalence in elderly populations. The existence of a common link between the two has been suggested despite a lack of clear pathological overlap in our current understanding. Research to date has tended to be fragmented and relatively weak in nature with multiple confounding factors reflecting the difficulties of *in vivo* experimentation in the population of interest. Despite exploration of various possible mechanisms in search for a link between the two pathologies, this paper found that it is possible that these associations are coincidental due to the nature of the evidence available. One finding in this review is that prior investigation into common aetiologies has found raised amyloid beta peptide levels in osteoporotic bone tissue, with a hypothesis that amyloid beta disorders are systemic disorders resulting in differing tissue manifestations. However, our findings were that the most compelling evidence of a common yet independent aetiology lies in the APOE4 allele, which is a well-established risk for AD but also carries an independent association with fracture risk. The mechanism behind this is thought to be the reduced plasma vitamin K levels in individuals exhibiting the APOE4 allele which may be amplified by the nutritional deficiencies associated with dementia, which are known to include vitamins K and D. The vitamin theory postulates that malnutrition and reduced exposure to sunlight in patients with AD leads to vitamin deficiencies.

***CONCLUSION***

Robust evidence remains to be produced regarding potential links and regarding the exact aetiology of these diseases and remains relevant given the burden of dementia and osteoporosis in our ageing population. Future research into amyloid beta, APOE4 and vitamins K and D as the most promising aetiological links should be welcomed.

**Key words:** Osteoporosis; Fracture; Dementia; Alzheimer’s disease; Elderly; Vitamin D; Vitamin K; Thyroid disease; Calcium; Statins; Alcohol; Sex steroids

**© The Author(s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** A potential pathological link between osteoporosis and dementia has been explored in observational studies, but there exists a lack of large scale randomised controlled trials. We hypothesise that dementia and osteoporosis have common yet independent aetiologies. The most compelling evidence lies in the APOE4 allele, a well-established risk factor for Alzheimer’s disease. APOE4 is associated with fracture, independent of dementia and falling. The mechanism behind this is postulated to be reduced plasma vitamin K levels in individuals exhibiting the APOE4 allele. This may be augmented by the nutritional deficiencies associated with dementia, known to include vitamins K and D.

Downey CL, Young A, Burton EF, Graham SM, Macfarlane RJ, Tsapakis EM, Tsiridis E. Dementia and osteoporosis in a geriatric population: Is there a common link? *World J Orthop* 2017; In press

**INTRODUCTION**

Dementia and osteoporosis are complex disease processes with similar epidemiology. Alzheimer’s disease (AD) is the most common form of dementia and increases from 16% in 75- to 84-year-old to 48% in over-85s[[1](#_ENREF_1)]. Osteoporosis affects 25% of women and 10% of men over 60[[2](#_ENREF_2)]. The two diseases co-exist in a subsection of the population, especially amongst females[[3](#_ENREF_3)]. Indeed, an odds ratio of 6.9 for fracture prevalence between people with and without AD has been reported[[4](#_ENREF_4)]. Thus a common link has been suggested despite no apparent pathological overlap.

The pathogenesis of AD lies in three complex mechanisms[[5](#_ENREF_5)]. The development of amyloid senile plaques causes neuronal death and phosphorylation of Tau proteins. Tau disassembles the microtubules resulting in neurofibrillary tangles and ultimately neuronal degeneration. Amyloid and Tau localise in the synapses, causing excessive calcium entry into post-synaptic neurons, necrosis and apoptosis. Despite extensive research into the disease, current treatment options are limited by their cost and efficacy. Their action lies in palliation of symptoms and most are only effective in a subsection of AD sufferers.

Osteoporosis is a progressive skeletal disease characterised by reduced bone density and micro-architectural bone destruction. This leads to increased bone fragility and susceptibility to fracture. Like dementia, the pathophysiology of osteoporosis is multifactorial and extends far past the traditional theory of nutritional calcium depletion. Indeed, both diseases have been associated with a number of other metabolic disturbances such as decreased vitamin D concentration and elevated serum parathyroid hormone, in addition to postulated common genetic variations such as the APOE4 allele[[2](#_ENREF_2)].

The burden of elderly care is a significant challenge to healthcare systems throughout the world and will only continue to grow in the coming decades. AD is the leading cause of loss of autonomy and independency in the elderly, and is associated with a number of comorbidities[[6](#_ENREF_6)]. Osteoporotic fractures have huge impact in terms of morbidity and mortality. Both diseases form part of the frailty syndrome, a collection of signs and symptoms associated with significant disability and public expenditure[[7](#_ENREF_7)]. Here we hypothesize that osteoporosis and dementia share a common predisposing aetiology. We propose that this is multifactorial, involving genetic, metabolic, endocrine and environmental factors. Elucidation of a common link between the two diseases could prove vital in the development of novel treatments for these complex medical and social problems.

**MATERIALS AND METHODS**

A comprehensive literature search of Ovid MEDLINE (1950 to June 2016) was conducted. The keywords “osteoporosis”, “osteoporotic fracture”, “dementia” and “Alzheimer’s disease” were used initially to determine the theoretical links with the most significant evidence base behind them. From manual study of key papers the lead investigators selected these to be vitamins D and K, calcium, thyroid disease, statins, alcohol and sex steroids. These subjects were searched in combination with the previous terms. Manual examination of titles and abstracts was used to exclude irrelevant articles. Theoretical, *in vitro* and *in vivo* research were all used to inform this review which focuses on the most well developed theoretical common causes for dementia (predominantly Alzheimer’s type) and osteoporosis.

**RESULTS**
***Vitamin D***

Approximately 1 billion adults are vitamin D deficient worldwide, and the prevalence is especially marked in older people, ranging from 50%-80%[[5](#_ENREF_5)]. Vitamin D has long been known for its effects on phosphocalcic metabolisms and bone[[5](#_ENREF_5)], thus vitamin D deficiency is well established as a risk factor for the development of osteoporosis[[8](#_ENREF_8)]. In contrast, the association between vitamin D and dementia requires clarification.

In 1995, Kipen *et al*[[8](#_ENREF_8)] found significantly lower vitamin D in women with dementia compared to cognitively-intact controls. A subsequent cross-sectional study found a vitamin D deficiency of < 10 ng/mL doubled the risk of cognitive impairment[[9](#_ENREF_9)]. A similar association between severe vitamin D deficiency (here defined as < 25 nmol/L at baseline) and mild cognitive impairment has been seen in elderly subjects over 65 years of age[[10](#_ENREF_10)].

A recent large Danish prospective study looked at participants who were free of cognitive impairment at enrolment and found that a decline in serum levels of vitamin D were associated with increased risk of participants developing AD[[11](#_ENREF_11)]. A more diverse American prospective study with a shorter length of follow up also found an association between baseline vitamin D deficiency (defined by the authors as serum levels < 50 nmol/L) and likelihood of participants developing AD and other all-cause dementias, an association that remained despite adjustment for mediators such as diabetes and hypertension[[12](#_ENREF_12)]. Both these studies looked at healthy participants who were ambulatory at enrolment[[11](#_ENREF_11),[12](#_ENREF_12)]. However reduced exposure to sunlight in patients with AD has been implicated as the main cause of vitamin D deficiency in patients with dementia[[13](#_ENREF_13)]. Patients with dementia are often immobile or housebound, and may be unable to gain sufficient sunlight exposure. Furthermore, generalised malnutrition either due to changes in functional ability, appetite disturbance, or disease may compound this problem.

In addition to environmental and functional changes, a decline in renal function accompanies the process of aging with the incidence of chronic kidney disease quoted as up to 35.8% in the geriatric population[[14](#_ENREF_14)]. Chronic renal disease results in impaired 1,25 dihydroxycholecalciferol production, the physiologically active metabolite within the body. Patients with suboptimal production of 1,25 dihydroxycholecalciferol may have this confirmed by low serum levels, and evidence of a secondary hyperparathyroidism[[15](#_ENREF_15)].

Aside from well-established physiological effects on bone metabolism, vitamin D has been found to play a pivotal role in both the normal function and protection of the central nervous system (CNS). As a neurosteroid hormone, vitamin D receptors are found in the neurons and glial cells of the CNS[[5](#_ENREF_5)]. The binding of 1,25 dihydroxycholecalciferol to these receptors results in a number of neuroprotective mechanisms. These can be categorised as direct, immune and homeostatic.

Directly, vitamin D inhibits the synthesis of nitric oxide synthase, an enzyme which promotes neuron alterations, and increases the synthesis of neurotrophic agents such as nerve growth factor[[5](#_ENREF_5)]. In addition, neuron-glial cell cultures treated with vitamin D show increased expression of genes known to limit the progression of AD[[16](#_ENREF_16)]. Vitamin D is also known to increase the number of macrophages and leukocytes in the brain. *In vitro* studies of macrophages from AD patients showed that stimulation with vitamin D increased phagocytosis and clearance of amyloid[[17](#_ENREF_17)]. Vitamin D plays an important role in the homeostasis of calcium and the avoidance of hyperparathyroidism by upregulating calcium channels and the synthesis of calcium-binding proteins[[5](#_ENREF_5)]. The importance of calcium and parathyroid status is discussed later.

Despite evidence *in vitro,* conclusive evidence of a link between vitamin D and dementia in patients is lacking (Table 1). In cross-sectional studies, vitamin D deficiency has been shown to double the risk of presenting with cognitive impairment[[9](#_ENREF_9)]. However, the nature of cross-sectional studies means that no cause and effect link can be made. Clearly, dementia may be the cause of reduced mobility and therefore reduced exposure to sunlight. A recent BMJ editorial criticised the perceived reliance on cross-sectional studies in relation to vitamin D as an aetiological factor in AD. It cited “a range of interpretational difficulties” such as reverse causality, confounding, classification bias and differences in assay methods[[18](#_ENREF_18)].

Nevertheless, in longitudinal studies, low baseline vitamin D levels have been found to predict incident cognitive decline in the elderly. A study of 858 Italians over the age of 65 showed that those who were “severely deficient” in vitamin D had a 1.6-fold increased risk of a substantial cognitive decline over 6 years, thus providing a temporal association[[19](#_ENREF_19)]. Another longitudinal study looking at time to progression to AD along with vitamin D treatment status, found that time to progression was longer in those treated with vitamin D (5.4 ± 0.4 years, *P* = 0.003) than in those who were not supplemented (4.4 ± 0.16 years, *P* = 0.003) but only in those who went on to develop severer manifestations of the disease[[20](#_ENREF_20)]. This study however was limited again by an observational study design and exclusion of some confounders from analysis, for example treatment with psychotropic medication[[20](#_ENREF_20)]. Pre-post studies, where cognitive function was measured before and after supplementation of vitamin D, found an improvement in cognition concomitant with the increase in vitamin D concentrations[[5](#_ENREF_5)]. There is only one, small randomised controlled trial on this topic, where 32 individuals with mild to moderate AD received low-dose vitamin D supplementation for 8 wk, before being randomised to either continue with the low dose (plus placebo) or to receive an additional high-dose supplement for a further 8 wk. Cognition was tested using a number of validated scales. Despite promising results from a smaller pilot study, the authors found that supraphysiological doses of vitamin D were no better than physiological doses at improving cognition or disability in this group, but acknowledge the limitations of such a small sample size[[21](#_ENREF_21)].

***Vitamin K***

Vitamin K is the collective term for a group of fat-soluble vitamins responsible for gamma-carboxylation of glutamate at various sites in the body. In the liver, vitamin K plays a vital role in the modification of prothrombin and other proteins responsible for haemostasis[[1](#_ENREF_1)]. In addition, vitamin K promotes bone health by means of site-specific carboxylation of osteocalcin (a marker of bone formation) and other bone matrix proteins such as matrix Gla-protein and protein S[[22](#_ENREF_22)]. In vitamin K deficiency, undercarboxylated osteocalcin is associated with osteoporosis and increased risk of fracture[[1](#_ENREF_1)]. A meta-analysis of 3 trials involving patients with neurological disease (AD, stroke and Parkinson’s Disease) showed that when vitamin K is replaced, there is a decreased risk of fractures compared to non-treatment[[23](#_ENREF_23)].

As with vitamin D, the link between vitamin K and osteoporosis is well-established, whilst any connection to dementia remains both multifactorial and largely theoretical. Numerous observational studies from Japan have indicated that vitamin K deficiencies contribute to reduced bone mineral density in patients with AD[[22](#_ENREF_22)]. A number of reasons have been postulated for the association between vitamin K deficiency and dementia including that of reverse causality.

It is plausible that, rather than vitamin K deficiency causing dementia, it is the dementia which affects vitamin K levels through malnutrition. Suboptimal dietary intake is evident even in the early stages of AD compared to cognitively intact age-matched controls[[24](#_ENREF_24)]. In humans, vitamin K1 is dietary, whilst K2 is synthesised by gut bacteria[[3](#_ENREF_3)]. In a cross-sectional study of 100 women with varying degrees of AD, BMI, bone mineral density and vitamin K1 levels were significantly lower in severe AD compared to mild AD[[3](#_ENREF_3)]. However, vitamin K2 levels were not significantly decreased, indicating a nutritional cause. Another study analysed the dietary vitamin K intakes of 31 patients with mild AD, compared to 31 controls. Vitamin K intakes were significantly less in patients with AD, even after adjusting for energy intake[[25](#_ENREF_25)].

Nevertheless, vitamin K does also appear to have a direct effect on the brain. Vitamin K-dependent gamma-carboxylation of glutamate in the liver and bone has already been discussed. This process is also apparent in the brain, by which growth-arrest-specific gene (*Gas6*) is biologically activated. Yagami *et al*[26] investigated the effect of *Gas6* in primary cultures of rat cortical neurons. *Gas6* was shown to protect against AD by the rescue of cortical neurons from amyloid-induced apoptosis[[26](#_ENREF_26)]. In addition, vitamin K is involved in sphingolipid synthesis. Sphingolipids are an important constituent of the myelin sheath and the neuron cell membrane, and alterations in sphingolipid metabolism have been identified in the brains of patients with mild AD[[25](#_ENREF_25)].

Alternatively, dementia and vitamin K deficiency may share a common cause. As previously discussed, apolipoprotein E4 (APOE4) is an allele that has been well-established as a risk factor for AD[[3](#_ENREF_3)]. APOE is found in chilomicrons which bind to vitamin K in plasma[[1](#_ENREF_1)]. APOE binds to a hepatic LDL receptor and LDL receptor-related protein (LRP); the variant APOE4 binds particularly quickly, thus reducing plasma vitamin K levels[[1](#_ENREF_1)]. The concentration of vitamin K is therefore lower in the circulating blood of APOE4 carriers[[1](#_ENREF_1)] and women expressing the APOE4 allele have been shown to have a significantly increased risk of osteoporotic hip fractures compared with those with other APOE genotypes[[27](#_ENREF_27)]. Another genotype, consisting of two copies of the apolipoprotein allele E2, has also been associated with increased frequency of vertebral fractures, suggesting further that apolipoprotein polymorphisms may play a role in bone mineral density and fracture risk[[28](#_ENREF_28)].

Although the association between vitamin K and dementia appears strong, there is little outside of cell work to prove a causal relationship. The evidence thus far lies in observational studies[[22](#_ENREF_22)] and a small number of randomised controlled trials in which vitamin K supplementation has been proven to reduce the risk of fractures in patients with neurological disease[[23](#_ENREF_23)]. This effect is assumed to be bone-mediated, and the possibility of improved cognitive function is not explored.

***Calcium and hyperparathyroidism***

Calcium has long been known to contribute to bone health. In combination with vitamin D, calcium promotes osteoblast differentiation and formation of mineralised bone, thus impairment in calcium signalling can contribute to the pathophysiology of osteoporosis[[29](#_ENREF_29)]. Likewise, the role of calcium homeostasis in the pathophysiology of dementia has been extensively investigated for almost three decades. The “calcium hypothesis” of the late 1980s[[30](#_ENREF_30)] postulates that “in the aging brain, transient or sustained increases in the average concentration of intracellular free calcium contribute to impaired function, eventually leading to cell death”. This hypothesis was supported by a range of animal and human studies, the earliest of which have been well-described by Disterhoft *et al*[[30](#_ENREF_30)]. For example, administration of magnesium, a calcium channel antagonist, to aging rats was shown to reduce calcium influx in hippocampal neurons and reverse functional and learning difficulties. Similarly, nimodipine, an isopropyl calcium channel antagonist that readily crosses the blood-brain barrier, was found by a recent Cochrane review to be of “some benefit in the treatment of patients with features of dementia due to unclassified disease or to AD, cerebrovascular disease, or mixed Alzheimer’s and cerebrovascular disease” although the authors stressed this benefit could only be applied to short-term outcomes[[31](#_ENREF_31)].

The role of calcium in the pathophysiology of impaired cognition is complex. Calcium is required for the function of all cells in the body, including neurons. The neurons of aged animals have been found to exhibit enhanced calcium activity compared to their younger counterparts[[32](#_ENREF_32)]. This has been attributed to an excess of calcium influx *via* voltage-gated calcium channels. Indeed, an increased density of these channels has been positively correlated with cognitive decline in animals. Further, in humans, enhanced intracellular calcium release from the endoplasmic reticulum has been found in the ageing brain, and research into this phenomenon continues[[32](#_ENREF_32)].

To propose that changes in calcium transport and metabolism forms the basis of link between osteoporosis and dementia seems counterintuitive, as the former may result from falling calcium levels, whist the latter has been attributed to high intracellular calcium. One possible mechanism is that calcium deficiency and the resultant secondary hyperparathyroidism results in bone loss whilst shifting calcium from the skeleton to the soft tissue, and from the extracellular to the intracellular compartments[[33](#_ENREF_33)]. Indeed a recent cross-sectional study has found association between high levels of PTH with low bone mineral density, which persisted even in participants where serum calcium levels were not overtly deficient[[34](#_ENREF_34)].

Increased parathyroid activity is well known to be associated with impaired cognitive function. Moreover, a recent 10-year longitudinal prospective study found that elevated PTH concentrations are associated with a five-year cognitive decline in a general aged population, although this was found to be independent of calcium concentrations[[35](#_ENREF_35)]. Further investigation would be required to establish a common role for calcium as a contributing factor to both osteoporosis and cognitive decline.

***Thyroid disease***

Overt thyroid disease is well known to be a reversible cause of cognitive impairment and altered bone metabolism[[36](#_ENREF_36)]. Subclinical thyroid disease - whereby normal levels of thyroxine (T4) and tri-iodothyronine (T3) are coupled with a deranged level of thyroid stimulating hormone (TSH) - is being increasingly recognised as a cause of significant morbidity and mortality within the elderly population[[37](#_ENREF_37)].

**Subclinical hyperthyroidism:** Subclinical hyperthyroidism (levels of T3 and T4 that are towards the top of the reference range coupled with reduced TSH, without symptoms of thyrotoxicosis) has been associated with various pathologies, and affects both bone mineral density and cognition[[38](#_ENREF_38)]. This may be due to exogenous causes, *i.e.*, excessive replacement with levothyroxine in hypothyroid patients; or endogenous causes such as Grave’s disease[[37](#_ENREF_37)].

There is considerable debate as to whether it is the level of TSH or of T4 itself that results in the physiological effects of thyroid hormone excess. A prospective study in Rotterdam found that individuals with subclinical hyperthyroidism had a greater than threefold increase in risk of developing dementia; with higher levels of T4 conferring greater risk. It is worth noting that none of these patients had a T4 level above the reference range[[36](#_ENREF_36)]. This finding is supported by a further retrospective study, which also demonstrated an association between elevated thyroid hormone levels and dementia, not related to the concentration of TSH. It therefore seems likely that the level of T4 is the important determinant[[39](#_ENREF_39)]. Furthermore, in a prospective cohort study of 665 Japanese-American men, followed-up for development of dementia after thyroid function was recorded, subsequent autopsy of one fifth of the cohort-including both healthy and demented patients-demonstrated that at higher levels of T4, more numerous intracerebral tangles and plaques are seen, as well as clinical dementia[[40](#_ENREF_40)].

Data regarding any association between osteoporosis and subclinical hyperthyroidism is unclear. Some studies show low levels of TSH appear to result in slightly reduced bone mineral density in men and post-menopausal women, but the protective effect of oestrogens means this does not generally apply in pre-menopausal women[[41](#_ENREF_41)]. The fifth Tromso population study in Norway, conducted in 2001, compared bone mineral density levels of TSH whilst adjusting for possible confounding factors such as weight and smoking. It discovered that, if TSH was normal, there was no relationship to bone mineral density; however, low TSH was seen in subjects with lower bone mineral density[[42](#_ENREF_42)]. T4 levels that are within the normal range are correlated with a lower level of bone mineral density at both the higher and lower ends of the spectrum - that is, in the region of subclinical thyroid disease[[36](#_ENREF_36),[43](#_ENREF_43)]. These hormone derangements are also associated with increased risk of fracture[[44](#_ENREF_44)].

**Subclinical hypothyroidism:** Subclinical hypothyroidism is a significant problem within the elderly population, and is more common than overt hypothyroidism[[45](#_ENREF_45)]. Despite the above discussion relating subclinical hyperthyroidism to cognitive impairment and dementia, patients with subclinical hypothyroidism have also been shown to be more likely to develop such attributes[[46](#_ENREF_46)]. This may be due to the effect of T4 itself, or reduced hormone concentration within the brain, resulting in slower information processing and increased susceptibility to cognitive dysfunction[[47](#_ENREF_47)]. It is also worth noting that treatment with levothyroxine has been shown to reduce cognitive impairment and improve mood in patients with mild hypothyroidism[[48](#_ENREF_48)]. Currently, although there is evidence that both states can cause cognitive decline, subclinical hyperthyroidism appears to have a stronger association with the development of dementia. A small scale study of 59 patients with multi-diagnosis dementia found a slight increase in TSH serum levels patients with AD compared to other diagnosis dementia patients and with healthy controls, along with a decrease in cerebrospinal fluid (CSF) total T4 levels in both patients with AD and those with other diagnoses compared to healthy controls[[49](#_ENREF_49)]. The CSF total T4 levels correlated positively with MMSE test scores and negatively with markers of axonal damage, which the authors hypothesized may mean that central levels of T4 are functionally important in AD[[49](#_ENREF_49)].

Despite the association between subclinical hypothyroidism and cognitive impairment, osteoporosis has not specifically been linked to subclinical hypothyroidism. Overtreatment of these patients with thyroxine has in fact been shown to lead to reduced bone mineral density and an increased rate of osteoporosis[[50](#_ENREF_50),[51](#_ENREF_51)]. This represents an important clinical disadvantage, and clinicians should exert caution in deciding whether or not to treat subclinical hypothyroidism[[51](#_ENREF_51)]. Subclinical thyroid disease is common in the elderly population, and has been shown to be associated with a number of co-morbidities- including osteoporosis and dementia in the case of subclinical hyperthyroidism. Additional work is required to establish if age-related changes in thyroid hormone concentrations represent a common factor in the aetiology of both conditions. Furthermore, investigating the treatment of subclinical disease, and whether or not it results in a lower rate of dementia and osteoporosis in the elderly, represents an exciting avenue for research in the future.

***Alcohol***

Excessive alcohol use is well known to result in low bone mineral density and increased risk of fracture[[52](#_ENREF_52)]. This has been thought to be due to a direct deleterious effect on osteoblast activity and subsequently a decrease in bone formation[[53](#_ENREF_53)], however this mechanism is not likely to be related to the development of dementia. Recently it has been suggested that lower levels of vitamin D in chronic alcoholics may be related to hepatic insufficiency and subsequently impaired metabolism of the substance[[54](#_ENREF_54)]. This could in turn affect bone formation. It must be remembered that low to moderate levels of alcohol intake does not reduce bone density; however, there has been no protective effect demonstrated either.

Whilst chronic excessive alcohol use leads to unique forms of dementia (*i.e.*, Korsakoff's syndrome) this is secondary to vitamin deficiencies, especially thiamine. Ethanol toxicity has been shown in rats to cause hippocampal and cortical cell loss, as well as loss of proteins required for neuronal survival[[55](#_ENREF_55)]. However, at low to moderate levels of intake there appears to be a protective effect against developing dementia[[56](#_ENREF_56),[57](#_ENREF_57)]. Interestingly, there was no protective effect seen in individuals with the APOE4 gene[[56](#_ENREF_56)]. The reasons for this protective effect are currently unclear.

It is difficult to assess whether alcohol intake is related to an increased risk of osteoporosis and dementia, especially given the likely protective effect of a moderate alcohol intake against dementia. The multiple comorbidities often experienced by chronic alcoholics (most notably nutrient deficiency) means studies are affected by a number of confounding factors. Varying patterns in form and frequency of alcohol abuse also make analysis difficult. Any link that were to be demonstrated would possibly be due to a secondary impact on another aspect of physiology (such as vitamin D deficiency), as opposed to an innate property of ethanol itself.

***Statins***

Statins (HMG CoA reductase inhibitors) are currently the target of a large volume of research given their supposed pleiotropic effects. As well as treating dyslipidaemia, statins have been proposed as being effective against malignancy, nephropathy, cataract formation and macular degeneration as well as against osteoporosis and dementia[[58](#_ENREF_58)].

The role of statins in reducing the risk of dementia was classically thought to be due to their role in reducing plaque formation, hence reducing vascular insults to the brain and the risk of ischaemic neuronal loss[[59](#_ENREF_59)]. Newer studies have proposed a systemic reduction in the inflammatory response, as evidenced by the ability of statins to reduce levels of C-reactive protein[[60](#_ENREF_60)]. Statins act on the mevalonate pathway, inhibiting conversion of HMG-CoA to mevalonate[[61](#_ENREF_61)]. Mevalonate is a precursor of the interleukin-6 group of cytokines which are implicated in systemic inflammation[[60](#_ENREF_60)]. It is possible that a reduction in systemic inflammation by inhibiting this pathway may help to prevent the development of dementia[[62](#_ENREF_62)].

Given the interest in the proposed mechanisms, Cochrane reviews have been held into randomised controlled trials of both the prevention and treatment of dementia by statins. They have found that despite marked reductions in serum low density cholesterol levels, statin use neither improves cognitive function in those with dementia nor does it reduce the incidence. The reviews conclude that there is insufficient evidence to recommend statins as either a prophylactic against, or treatment for, dementia[[63](#_ENREF_63),[64](#_ENREF_64)].

New theories on the development of osteoporosis hold that the mechanism is similar to that whereby lipids are oxidised[[65](#_ENREF_65)]. If statins were shown to act directly on this mechanism then a beneficial effect in osteoporosis would also be likely. *In vitro* studies investigating mechanisms by which statins stimulate osteoblast differentiation have demonstrated that they exert their effects *via* the SMAD and the bone morphogenetic protein-2 (BMP-2) signalling pathways[[66](#_ENREF_66)]. A recent review of *in vitro* and *in vivo* data suggests that statins also act *via* the RANKL pathway, which has been implicated in both adipogenesis and in changing osteoclastic activity, leading to osteoporosis[[67](#_ENREF_67)].

Whilst there are theoretical benefits of statins in both dementia and osteoporosis, they have yet to be demonstrated in clinical studies. A large meta-analysis of hip bone mineral density showed a small but statistically significant benefit in patients taking statins[[68](#_ENREF_68)]. However, this advantage does not translate into a decreased risk of fracture, according to a systematic review of studies observing fracture incidence in patients taking statins[[69](#_ENREF_69)]. A recent RCT has also failed to demonstrate the benefit of specific statins in decreasing fracture risk[[70](#_ENREF_70)]. Further evidence is required before routine statin use can be recommended for the prevention or treatment of either condition.

***Androgens and oestrogens***

Sex steroids play important roles in reproductive function, and in recent years receptors for these hormones have been identified in a range of body tissues, including bone and the nervous system[[71](#_ENREF_71)]. The relationship between ageing, falling levels of sex steroids, and the subsequent reduction in bone mineral density is well described and a cause of much morbidity in the elderly population. Reduction in oestrogen levels in women is known to result in increased osteoclast activity and bone resorption[[72](#_ENREF_72)]. The androgens are also known to be important in maintaining bone mineral density, both through intrinsic activity and as a result of aromatization to oestrogens[[73](#_ENREF_73)]. Androgen activity gradually reduces in later male life, hence the resulting increase in rates of osteoporosis in older men. Whilst administration of endogenous sex steroids in the form of hormone replacement therapy in post-menopausal women does reduce the risk of fracture, it is no longer recommended for the prevention of osteoporosis due to cardiovascular side-effects[[74](#_ENREF_74)]. Newer theories propose that oxidative stress holds an important role in the development of osteoporosis, and that sex steroids are important in protecting against this[[65](#_ENREF_65)]. This would represent a possible therapeutic target with statin agents, if such a mechanism is proven.

Androgens and oestrogens have been suggested as being protective against AD, given that cognitive impairment is associated with a decrease in testosterone levels[[75](#_ENREF_75)]. Animal studies have shown increased neuronal activity when testosterone supplements are administered, but the data from clinical trials is disappointingly inconclusive[[75](#_ENREF_75)]. Additionally, the role of oestrogen in both preventing cognitive decline in intellectually normal women, and in maintaining cognitive function in patients with AD, has been the subject of a number of systematic reviews. Insufficient evidence for any beneficial effect was found for oestrogen administration in all studies reviewed[[76](#_ENREF_76),[77](#_ENREF_77)]. Moreover, one review of long-term hormone replacement therapy found that in healthy women aged over 65 there was an increased incidence of dementia[[74](#_ENREF_74)], although this is unlikely to be due to a direct effect of hormone replacement, and may simply be a result of an increase in frequency of cardiovascular events, a known independent risk factor for developing dementia. There has been recent animal work looking at the effects of sex steroid analogues, so called selective androgen receptor agonists (SARMs) and selective estrogen receptor agonists, which are thought to allow for the beneficial effects of the sex steroids in protecting against neurodegenerative disorders whilst avoiding detrimental cardiovascular tissue effects which may also contribute to development of dementia[[78](#_ENREF_78)]. Such analogues are thought to interfere in the progression of AD by aiding clearance of amyloid beta peptides from neurological tissue[[78](#_ENREF_78)]. In the treated mice there were decreased levels of amyloid beta, along with increased levels of amyloid beta clearing enzymes and improved long term memory[[78](#_ENREF_78)].

The evidence surrounding changes in sex steroid levels and dementia is inconclusive. There is no firm evidence for a beneficial effect of androgen administration, and the increase in frequency of cardiovascular events causes significant morbidity and may increase the prevalence of dementia itself. This may be due to the significant increase in cholesterol levels associated with falling androgen levels[[79](#_ENREF_79)]. Additionally, the low levels of androgens demonstrated in some men with dementia may be unrelated or may be secondary to the disease itself.

**DISCUSSION**

Despite various possible mechanisms for a link between the two pathologies, it is also quite possible that these associations are coincidental and not related to a common aetiological factor. Only one such investigation into common aetiologies exists in a 2014 study which found raised amyloid beta peptide levels in osteoporotic bone tissue compared to age matched controls in female patients[[80](#_ENREF_80)]. The level of amyloid beta expression negatively correlated with bone density levels in this study[[80](#_ENREF_80)]. Amyloid beta was found to also have an impact on osteoclast differentiation and activation, implying it may play a role in the pathological processes of osteoporosis[[80](#_ENREF_80)]. Authors hypothesized amyloid beta disorders to be systemic disorders resulting in differing tissue manifestations[[80](#_ENREF_80)], yet robust evidence remains to be produced regarding this link and regarding the exact aetiology of amyloid beta in AD.

People with dementia are more prone to falls and fractures due to cognitive and behavioural disorders, visual and motor problems, gait and balance disturbances, malnutrition, and the adverse effects of medication[[81](#_ENREF_81)]. Thus there may be a higher pick-up rate for osteoporosis amongst this group. However, a population-based study of more than 2600 elderly people found that those with dementia received less preventative treatment for osteoporosis compared to people without dementia[[82](#_ENREF_82)]. In patients who have received the appropriate prescription, efficacy may be diminished in patients with dementia due to factors such as medical comorbidities, polypharmacy, lack of adherence, substance abuse, delirium and inadequate social support[[83](#_ENREF_83)].

Nevertheless, we hypothesise that dementia and osteoporosis have common aetiologies as significant counterevidence exists in recent literature. There remains a significant increased prevalence of osteoporosis in AD sufferers in large scale observational studies compared to the general population, with an odds ratio for femoral fracture amongst a French female population the same as that of other severe systemic illnesses (OR = 4, *P* < 0.0001). The mortality and morbidity associated with such fractures in elderly populations prompts continued interest in this area of research[84].Furthermore, following femoral neck fracture treatment and subsequent inpatient stays, this subsection of the population has been found to have poor return to previous functional states as measured by residential status, along with poor 30-d mortality compared to patients without dementia[85]. Other very large scale observational studies have had compelling results in favour of a potential link, with Chang *et al*[86] finding a 1.46-fold and 1.39-fold higher risk of dementia (95%CI: 1.37-1.56) and AD (95%CI: 0.95-2.02) in osteoporosis patients studied, whilst adjusting for potential confounders such as comorbid disease. This Taiwanese cohort also demonstrated a negative correlation between treatment for osteoporosis (such as bisphosphonates) and the risk of dementia, with the most marked negative correlation found in those taking bisphosphonates and oestrogens[86].However, patients with dementia have repeatedly been found to be least likely to be prescribed osteoporosis treatments which may have such protective effects both in terms of fracture risk and cognitive health[87].Despite these recent findings, the same limitations to such large scale retrospective studies apply and further RCTs would be required to provide higher quality evidence of such links despite the varied evidence explored in this paper.

The most compelling evidence for a common aetiology is the APOE4 allele, a major cholesterol carrier, and a well-established genetic risk factor for AD *via* its binding to Amyloid beta peptide and its potential role in deposition of senile plaques[[3](#_ENREF_3)]. APOE4 has also been found to be associated with fracture, independent of dementia and falling[[27](#_ENREF_27)]. The mechanism behind this effect on fracture risk is postulated to be the reduced plasma vitamin K levels in individuals exhibiting the APOE4 allele, which binds vitamin K in the plasma and promotes its uptake into the liver more rapidly than other APOE variants. Women who express this allele have a higher risk of osteoporotic fractures than other APOE genotypes found in the general population[1].This may be multifactorial in its effect and augmented by the nutritional deficiencies associated with dementia, which are known to include vitamins K and D. In particular, vitamins D and K are known to play a role in the both bone matrix stability and neuronal protection in the CNS. The vitamin theory postulates that malnutrition and reduced exposure to sunlight in patients with AD leads to vitamin deficiencies.

Robust evidence of an underlying pathophysiological link between osteoporosis and dementia would potentially transform the care of the older adult. Research to date has tended to be fragmented and of a relatively weak nature with multiple confounding factors reflecting the difficulties of in vivo experimentation in the population of interest. A suggestion for future work would include randomised controlled trials of vitamin supplementation *vs* placebo, stratified for APOE4 and hormone status. As our understanding of the molecular basis of osteoporosis and dementia improves, new therapeutic targets should become apparent.

**COMMENTS**

***Background***

Dementia and osteoporosis are diseases processes with similar epidemiology and increasing prevalence in the elderly, where the two coexist in a subsection of the population especially amongst females. The burden of elderly care continues to be a significant challenge to healthcare systems globally. Alzheimer’s disease (AD) is the leading cause of loss of independence and autonomy in the elderly and osteoporotic fractures have a huge impact in this patient population in terms of morbidity and mortality. An odds ratio of 6.9 for fracture prevalence between people with and without AD has been reported. In current understanding of the disease aetiologies no pathological overlap has been identified but a common link has been postulated to exist. The pathogenesis of AD is currently understood to involve development of amyloid plaques causing neuronal death and subsequent phosphorylation of Tau proteins, which ultimately cause further neuronal degeneration and the localisation of these two abnormal proteins in the synapses causes post-synaptic neuronal death *via* calcium influx. Despite extensive research into AD and its multifactorial pathophysiology, current treatments are limited by cost and efficacy and their action lies in palliation of symptoms. Osteoporosis in contrast is a progressive skeletal disease characterised by reduced bone density and micro-architectural bone destruction leading to increased susceptibility to fracture. Both diseases have multifactorial pathophysiology and have been associated with other metabolic disturbances including decreased vitamin D levels and elevated parathyroid hormone. Other genetic variants such as the APOE4 allele have also been postulated to link their pathophysiology.

***Research frontiers***

Both osteoporosis and AD form part of frailty syndrome, a collection of signs and symptoms associated with significant disability in the elderly population and increased public expenditure in healthcare and social care systems. This paper hypothesizes that both diseases share a common predisposing aetiology, which may be multifactorial and involve genetic, metabolic, endocrine and environmental factors.

***Innovations and breakthroughs***

Many studies have been conducted in the last 60 years exploring various aspects of the pathophysiology of both osteoporosis and dementia as both diseases represent significant burdens upon the affected populations. However very few have been higher tier research designs such as randomised control trials or specifically examined an aetiological link as addressed by the research question of this paper. The authors’ key findings were that the most compelling evidence of a common yet independent aetiology lies in the APOE4 allele, which is a well-established risk for Alzheimer’s disease but also carries an independent association with fracture risk and so osteoporosis. The mechanism behind this is thought to be the reduced plasma vitamin K levels in individuals exhibiting the APOE4 allele which may be amplified by the nutritional deficiencies associated with dementia, which are known to include vitamins K and D. The vitamin theory postulates that malnutrition and reduced exposure to sunlight in patients with AD leads to vitamin deficiencies which are then well associated with increased risk of fracture.

***Applications***

Discovery of a common aetiological link between the two may prove key in development of novel treatments for these complex medical and social problems. This study found that research to date on this topic has tended to be fragmented and of a relatively weak nature with multiple confounding factors, which may reflect inherent difficulties of *in vivo* experimentation in the population of interest. Despite many theoretical links between the two diseases, there is a lack of systematic high level evidence and as such the link between the two remains theoretical. This study may help direct design of future large scale studies or RCTs in the affected population groups.

***Peer-review***

This is an interesting study, and what is reviewed is well done.

**REFERENCES**

1 **Allison AC**. The possible role of vitamin K deficiency in the pathogenesis of Alzheimer's disease and in augmenting brain damage associated with cardiovascular disease. *Med Hypotheses* 2001; **57**: 151-155 [PMID: 11461163 DOI: 10.1054/mehy.2001.1307]

2 **Tysiewicz-Dudek M**, Pietraszkiewicz F, Drozdzowska B. Alzheimer's disease and osteoporosis: common risk factors or one condition predisposing to the other? *Ortop Traumatol Rehabil* 2008; **10**: 315-323 [PMID: 18779764]

3 **Sato Y**, Honda Y, Hayashida N, Iwamoto J, Kanoko T, Satoh K. Vitamin K deficiency and osteopenia in elderly women with Alzheimer's disease. *Arch Phys Med Rehabil* 2005; **86**: 576-581 [PMID: 15759247 DOI: 10.1016/j.apmr.2004.10.005]

4 **Buchner DM**, Larson EB. Falls and fractures in patients with Alzheimer-type dementia. *JAMA* 1987; **257**: 1492-1495 [PMID: 3820464]

5 **Annweiler C**, Beauchet O. Vitamin D-mentia: randomized clinical trials should be the next step. *Neuroepidemiology* 2011; **37**: 249-258 [PMID: 22156654 DOI: 10.1159/000334177]

6 **Annweiler C**, Fantino B, Parot-Schinkel E, Thiery S, Gautier J, Beauchet O. Alzheimer's disease--input of vitamin D with mEmantine assay (AD-IDEA trial): study protocol for a randomized controlled trial. *Trials* 2011; **12**: 230 [PMID: 22014101 DOI: 10.1186/1745-6215-12-230]

7 **Heuberger RA**. The frailty syndrome: a comprehensive review. *J Nutr Gerontol Geriatr* 2011; **30**: 315-368 [PMID: 22098178 DOI: 10.1080/21551197.2011.623931]

8 **Kipen E**, Helme RD, Wark JD, Flicker L. Bone density, vitamin D nutrition, and parathyroid hormone levels in women with dementia. *J Am Geriatr Soc* 1995; **43**: 1088-1091 [PMID: 7560696 DOI: 10.1111/j.1532-5415.1995.tb07005.x]

9 **Annweiler C**, Schott AM, Allali G, Bridenbaugh SA, Kressig RW, Allain P, Herrmann FR, Beauchet O. Association of vitamin D deficiency with cognitive impairment in older women: cross-sectional study. *Neurology* 2010; **74**: 27-32 [PMID: 19794127 DOI: 10.1212/WNL.0b013e3181beecd3]

10 **Moon JH**, Lim S, Han JW, Kim KM, Choi SH, Kim KW, Jang HC. Serum 25-hydroxyvitamin D level and the risk of mild cognitive impairment and dementia: the Korean Longitudinal Study on Health and Aging (KLoSHA). *Clin Endocrinol* (Oxf) 2015; **83**: 36-42 [PMID: 25641087 DOI: 10.1111/cen.12733]

11 **Afzal S**, Bojesen SE, Nordestgaard BG. Reduced 25-hydroxyvitamin D and risk of Alzheimer's disease and vascular dementia. *Alzheimers Dement* 2014; **10**: 296-302 [PMID: 23871764 DOI: 10.1016/j.jalz.2013.05.1765]

12 **Littlejohns TJ**, Henley WE, Lang IA, Annweiler C, Beauchet O, Chaves PH, Fried L, Kestenbaum BR, Kuller LH, Langa KM, Lopez OL, Kos K, Soni M, Llewellyn DJ. Vitamin D and the risk of dementia and Alzheimer disease. *Neurology* 2014; **83**: 920-928 [PMID: 25098535 DOI: 10.1212/WNL.0000000000000755]

13 **Sato Y**. [Dementia and fracture]. *Clin Calcium* 2010; **20**: 1379-1384 [PMID: 20808046]

14 **Zhang QL**, Rothenbacher D. Prevalence of chronic kidney disease in population-based studies: systematic review. *BMC Public Health* 2008; **8**: 117 [PMID: 18405348 DOI: 10.1186/1471-2458-8-117]

15 **Fujita T**. Biological effects of aging on bone and the central nervous system. *Exp Gerontol* 1990; **25**: 317-321 [PMID: 2226667 DOI: 10.1016/0531-5565(90)90068-D]

16 **Nissou MF**, Brocard J, El Atifi M, Guttin A, Andrieux A, Berger F, Issartel JP, Wion D. The transcriptomic response of mixed neuron-glial cell cultures to 1,25-dihydroxyvitamin d3 includes genes limiting the progression of neurodegenerative diseases. *J Alzheimers Dis* 2013; **35**: 553-564 [PMID: 23455988 DOI: 10.3233/JAD-122005]

17 **Masoumi A**, Goldenson B, Ghirmai S, Avagyan H, Zaghi J, Abel K, Zheng X, Espinosa-Jeffrey A, Mahanian M, Liu PT, Hewison M, Mizwickie M, Cashman J, Fiala M. 1alpha,25-dihydroxyvitamin D3 interacts with curcuminoids to stimulate amyloid-beta clearance by macrophages of Alzheimer's disease patients. *J Alzheimers Dis* 2009; **17**: 703-717 [PMID: 19433889 DOI: 10.3233/JAD-2009-1080]

18 **Harvey NC**, Cooper C. Vitamin D: some perspective please. *BMJ* 2012; **345**: e4695 [PMID: 22815431]

19 **Llewellyn DJ**, Lang IA, Langa KM, Muniz-Terrera G, Phillips CL, Cherubini A, Ferrucci L, Melzer D. Vitamin D and risk of cognitive decline in elderly persons. *Arch Intern Med* 2010; **170**: 1135-1141 [PMID: 20625021 DOI: 10.1001/archinternmed.2010.173]

20 **Chaves M**, Toral A, Bisonni A, Rojas JI, Fernández C, García Basalo MJ, Matusevich D, Cristiano E, Golimstok A. [Treatment with vitamin D and slowing of progression to severe stage of Alzheimer's disease]. *Vertex* 2014; **25**: 85-91 [PMID: 25153973]

21 **Stein MS**, Scherer SC, Ladd KS, Harrison LC. A randomized controlled trial of high-dose vitamin D2 followed by intranasal insulin in Alzheimer's disease. *J Alzheimers Dis* 2011; **26**: 477-484 [PMID: 21694461 DOI: 10.3233/JAD-2011-110149]

22 **Sato Y**, Kanoko T, Satoh K, Iwamoto J. Menatetrenone and vitamin D2 with calcium supplements prevent nonvertebral fracture in elderly women with Alzheimer's disease. *Bone* 2005; **36**: 61-68 [PMID: 15664003 DOI: 10.1016/j.bone.2004.09.018]

23 **Iwamoto J**, Matsumoto H, Takeda T. Efficacy of menatetrenone (vitamin K2) against non-vertebral and hip fractures in patients with neurological diseases: meta-analysis of three randomized, controlled trials. *Clin Drug Investig* 2009; **29**: 471-479 [PMID: 19499964 DOI: 10.2165/00044011-200929070-00005]

24 **Shatenstein B**, Kergoat MJ, Reid I. Poor nutrient intakes during 1-year follow-up with community-dwelling older adults with early-stage Alzheimer dementia compared to cognitively intact matched controls. *J Am Diet Assoc* 2007; **107**: 2091-2099 [PMID: 18060894 DOI: 10.1016/j.jada.2007.09.008]

25 **Presse N**, Shatenstein B, Kergoat MJ, Ferland G. Low vitamin K intakes in community-dwelling elders at an early stage of Alzheimer's disease. *J Am Diet Assoc* 2008; **108**: 2095-2099 [PMID: 19027415 DOI: 10.1016/j.jada.2008.09.013]

26 **Yagami T**, Ueda K, Asakura K, Sakaeda T, Nakazato H, Kuroda T, Hata S, Sakaguchi G, Itoh N, Nakano T, Kambayashi Y, Tsuzuki H. Gas6 rescues cortical neurons from amyloid beta protein-induced apoptosis. *Neuropharmacology* 2002; **43**: 1289-1296 [PMID: 12527478 DOI: 10.1016/S0028-3908(02)00333-7]

27 **Johnston JM**, Cauley JA, Ganguli M. APOE 4 and hip fracture risk in a community-based study of older adults. *J Am Geriatr Soc* 1999; **47**: 1342-1345 [PMID: 10573444 DOI: 10.1111/j.1532-5415.1999.tb07436.x]

28 **Zhang SQ**, Zhang WY, Ye WQ, Zhang LJ, Fan F. Apolipoprotein E gene E2/E2 genotype is a genetic risk factor for vertebral fractures in humans: a large-scale study. *Int Orthop* 2014; **38**: 1665-1669 [PMID: 24880936 DOI: 10.1007/s00264-014-2380-4]

29 **Peterlik M**, Kállay E, Cross HS. Calcium nutrition and extracellular calcium sensing: relevance for the pathogenesis of osteoporosis, cancer and cardiovascular diseases. *Nutrients* 2013; **5**: 302-327 [PMID: 23340319 DOI: 10.3390/nu5010302]

30 **Disterhoft JF**, Moyer JR, Thompson LT. The calcium rationale in aging and Alzheimer's disease. Evidence from an animal model of normal aging. *Ann N Y Acad Sci* 1994; **747**: 382-406 [PMID: 7847686 DOI: 10.1111/j.1749-6632.1994.tb44424.x]

31 **López-Arrieta JM**, Birks J. Nimodipine for primary degenerative, mixed and vascular dementia. *Cochrane Database Syst Rev* 2002; **(3)**: CD000147 [PMID: 12137606 DOI: 10.1002/14651858.CD000147]

32 **Thibault O**, Gant JC, Landfield PW. Expansion of the calcium hypothesis of brain aging and Alzheimer's disease: minding the store. *Aging Cell* 2007; **6**: 307-317 [PMID: 17465978 DOI: 10.1111/j.1474-9726.2007.00295.x]

33 **Fujita T**. Aging and calcium as an environmental factor. *J Nutr Sci Vitaminol* (Tokyo) 1985; **31** Suppl: S15-S19 [PMID: 2943880 DOI: 10.3177/jnsv.31.Supplement\_S15]

34 **Berger C**, Almohareb O, Langsetmo L, Hanley DA, Kovacs CS, Josse RG, Adachi JD, Prior JC, Towheed T, Davison KS, Kaiser SM, Brown JP, Goltzman D. Characteristics of hyperparathyroid states in the Canadian multicentre osteoporosis study (CaMos) and relationship to skeletal markers. *Clin Endocrinol* (Oxf) 2015; **82**: 359-368 [PMID: 25059283 DOI: 10.1111/cen.12569]

35 **Björkman MP**, Sorva AJ, Tilvis RS. Does elevated parathyroid hormone concentration predict cognitive decline in older people? *Aging Clin Exp Res* 2010; **22**: 164-169 [PMID: 19934619 DOI: 10.3275/6626]

36 **Kalmijn S**, Mehta KM, Pols HA, Hofman A, Drexhage HA, Breteler MM. Subclinical hyperthyroidism and the risk of dementia. The Rotterdam study. *Clin Endocrinol* (Oxf) 2000; **53**: 733-737 [PMID: 11155096 DOI: 10.1046/j.1365-2265.2000.01146.x]

37 **Biondi B**. Natural history, diagnosis and management of subclinical thyroid dysfunction. *Best Pract Res Clin Endocrinol Metab* 2012; **26**: 431-446 [PMID: 22863386 DOI: 10.1016/j.beem.2011.12.004]

38 **Santos Palacios S**, Pascual-Corrales E, Galofre JC. Management of subclinical hyperthyroidism. *Int J Endocrinol Metab* 2012; **10**: 490-496 [PMID: 23843809 DOI: 10.5812/ijem.3447]

39 **Vadiveloo T**, Donnan PT, Cochrane L, Leese GP. The Thyroid Epidemiology, Audit, and Research Study (TEARS): morbidity in patients with endogenous subclinical hyperthyroidism. *J Clin Endocrinol Metab* 2011; **96**: 1344-1351 [PMID: 21346066 DOI: 10.1210/jc.2010-2693]

40 **de Jong FJ**, Masaki K, Chen H, Remaley AT, Breteler MM, Petrovitch H, White LR, Launer LJ. Thyroid function, the risk of dementia and neuropathologic changes: the Honolulu-Asia aging study. *Neurobiol Aging* 2009; **30**: 600-606 [PMID: 17870208 DOI: 10.1016/j.neurobiolaging.2007.07.019]

41 **Nicholls JJ**, Brassill MJ, Williams GR, Bassett JH. The skeletal consequences of thyrotoxicosis. *J Endocrinol* 2012; **213**: 209-221 [PMID: 22454529 DOI: 10.1530/JOE-12-0059]

42 **Grimnes G**, Emaus N, Joakimsen RM, Figenschau Y, Jorde R. The relationship between serum TSH and bone mineral density in men and postmenopausal women: the Tromsø study. *Thyroid* 2008; **18**: 1147-1155 [PMID: 18925834 DOI: 10.1089/thy.2008.0158]

43 **Lin JD**, Pei D, Hsia TL, Wu CZ, Wang K, Chang YL, Hsu CH, Chen YL, Chen KW, Tang SH. The relationship between thyroid function and bone mineral density in euthyroid healthy subjects in Taiwan. *Endocr Res* 2011; **36**: 1-8 [PMID: 21226562 DOI: 10.3109/07435800.2010.514877]

44 **Bauer DC**, Ettinger B, Nevitt MC, Stone KL. Risk for fracture in women with low serum levels of thyroid-stimulating hormone. *Ann Intern Med* 2001; **134**: 561-568 [PMID: 12803168 DOI: 10.7326/0003-4819-134-7-200104030-00009]

45 **Davis JD**, Tremont G. Neuropsychiatric aspects of hypothyroidism and treatment reversibility. *Minerva Endocrinol* 2007; **32**: 49-65 [PMID: 17353866]

46 **Resta F**, Triggiani V, Barile G, Benigno M, Suppressa P, Giagulli VA, Guastamacchia E, Sabbà C. Subclinical hypothyroidism and cognitive dysfunction in the elderly. *Endocr Metab Immune Disord Drug Targets* 2012; **12**: 260-267 [PMID: 22385117 DOI: 10.2174/187153012802002875]

47 **Davis JD**, Stern RA, Flashman LA. Cognitive and neuropsychiatric aspects of subclinical hypothyroidism: significance in the elderly. *Curr Psychiatry Rep* 2003; **5**: 384-390 [PMID: 13678560 DOI: 10.1007/s11920-003-0073-6]

48 **Bono G**, Fancellu R, Blandini F, Santoro G, Mauri M. Cognitive and affective status in mild hypothyroidism and interactions with L-thyroxine treatment. *Acta Neurol Scand* 2004; **110**: 59-66 [PMID: 15180808 DOI: 10.1111/j.1600-0404.2004.00262.x]

49 **Johansson P**, Almqvist EG, Johansson JO, Mattsson N, Hansson O, Wallin A, Blennow K, Zetterberg H, Svensson J. Reduced cerebrospinal fluid level of thyroxine in patients with Alzheimer's disease. *Psychoneuroendocrinology* 2013; **38**: 1058-1066 [PMID: 23159010 DOI: 10.1016/j.psyneuen.2012.10.012]

50 **Tárraga López PJ**, López CF, de Mora FN, Montes JA, Albero JS, Mañez AN, Casas AG. Osteoporosis in patients with subclinical hypothyroidism treated with thyroid hormone. *Clin Cases Miner Bone Metab* 2011; **8**: 44-48 [PMID: 22461829]

51 **Khandelwal D**, Tandon N. Overt and subclinical hypothyroidism: who to treat and how. *Drugs* 2012; **72**: 17-33 [PMID: 22191793 DOI: 10.2165/11598070-000000000-00000]

52 **Drake MT**, Murad MH, Mauck KF, Lane MA, Undavalli C, Elraiyah T, Stuart LM, Prasad C, Shahrour A, Mullan RJ, Hazem A, Erwin PJ, Montori VM. Clinical review. Risk factors for low bone mass-related fractures in men: a systematic review and meta-analysis. *J Clin Endocrinol Metab* 2012; **97**: 1861-1870 [PMID: 22466344 DOI: 10.1210/jc.2011-3058]

53 **Chen Y**, Wu T, Cui L. Research advances in alcoholic osteoporosis. *Chinese Journal of Clinical Nutrition* 2006; **14**: 131-133

54 **Maurel DB**, Boisseau N, Benhamou CL, Jaffre C. Alcohol and bone: review of dose effects and mechanisms. *Osteoporos Int* 2012; **23**: 1-16 [PMID: 21927919 DOI: 10.1007/s00198-011-1787-7]

55 **Vetreno RP**, Hall JM, Savage LM. Alcohol-related amnesia and dementia: animal models have revealed the contributions of different etiological factors on neuropathology, neurochemical dysfunction and cognitive impairment. *Neurobiol Learn Mem* 2011; **96**: 596-608 [PMID: 21256970 DOI: 10.1016/j.nlm.2011.01.003]

56 **Neafsey EJ**, Collins MA. Moderate alcohol consumption and cognitive risk. *Neuropsychiatr Dis Treat* 2011; **7**: 465-484 [PMID: 21857787 DOI: 10.2147/NDT.S23159]

57 **Kim JW**, Lee DY, Lee BC, Jung MH, Kim H, Choi YS, Choi IG. Alcohol and cognition in the elderly: a review. *Psychiatry Investig* 2012; **9**: 8-16 [PMID: 22396679 DOI: 10.4306/pi.2012.9.1.8]

58 **Beri A**, Sural N, Mahajan SB. Non-atheroprotective effects of statins: a systematic review. *Am J Cardiovasc Drugs* 2009; **9**: 361-370 [PMID: 19929034 DOI: 10.2165/11315710-000000000-00000]

59 **Wang Q**, Yan J, Chen X, Li J, Yang Y, Weng J, Deng C, Yenari MA. Statins: multiple neuroprotective mechanisms in neurodegenerative diseases. *Exp Neurol* 2011; **230**: 27-34 [PMID: 20406638 DOI: 10.1016/j.expneurol.2010.04.006]

60 **Omoigui S**. The Interleukin-6 inflammation pathway from cholesterol to aging--role of statins, bisphosphonates and plant polyphenols in aging and age-related diseases. *Immun Ageing* 2007; **4**: 1 [PMID: 17374166 DOI: 10.1186/1742-4933-4-1]

61 **Bonetti PO**, Lerman LO, Napoli C, Lerman A. Statin effects beyond lipid lowering--are they clinically relevant? *Eur Heart J* 2003; **24**: 225-248 [PMID: 12590901]

62 **Buhaescu I**, Izzedine H. Mevalonate pathway: a review of clinical and therapeutical implications. *Clin Biochem* 2007; **40**: 575-584 [PMID: 17467679 DOI: 10.1016/j.clinbiochem.2007.03.016]

63 **McGuinness B**, O'Hare J, Craig D, Bullock R, Malouf R, Passmore P. Cochrane review on 'Statins for the treatment of dementia'. *Int J Geriatr Psychiatry* 2013; **28**: 119-126 [PMID: 22473869 DOI: 10.1002/gps.3797]

64 **McGuinness B**, Craig D, Bullock R, Passmore P. Statins for the prevention of dementia. *Cochrane Database Syst Rev* 2009; **(2)**: CD003160 [PMID: 19370582 DOI: 10.1002/14651858.CD003160.pub2]

65 **Manolagas SC**. From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis. *Endocr Rev* 2010; **31**: 266-300 [PMID: 20051526 DOI: 10.1210/er.2009-0024]

66 **Chen PY**, Sun JS, Tsuang YH, Chen MH, Weng PW, Lin FH. Simvastatin promotes osteoblast viability and differentiation via Ras/Smad/Erk/BMP-2 signaling pathway. *Nutr Res* 2010; **30**: 191-199 [PMID: 20417880 DOI: 10.1016/j.nutres.2010.03.004]

67 **Tsartsalis AN**, Dokos C, Kaiafa GD, Tsartsalis DN, Kattamis A, Hatzitolios AI, Savopoulos CG. Statins, bone formation and osteoporosis: hope or hype? *Hormones* (Athens) 2012; **11**: 126-139 [PMID: 22801558 DOI: 10.14310/horm.2002.1339]

68 **Uzzan B**, Cohen R, Nicolas P, Cucherat M, Perret GY. Effects of statins on bone mineral density: a meta-analysis of clinical studies. *Bone* 2007; **40**: 1581-1587 [PMID: 17409043 DOI: 10.1016/j.bone.2007.02.019]

69 **Toh S**, Hernández-Díaz S. Statins and fracture risk. A systematic review. *Pharmacoepidemiol Drug Saf* 2007; **16**: 627-640 [PMID: 17286319 DOI: 10.1002/pds.1363]

70 **Peña JM**, Aspberg S, MacFadyen J, Glynn RJ, Solomon DH, Ridker PM. Statin therapy and risk of fracture: results from the JUPITER randomized clinical trial. *JAMA Intern Med* 2015; **175**: 171-177 [PMID: 25437881 DOI: 10.1001/jamainternmed.2014.6388]

71 **Fauser BC**, Laven JS, Tarlatzis BC, Moley KH, Critchley HO, Taylor RN, Berga SL, Mermelstein PG, Devroey P, Gianaroli L, D'Hooghe T, Vercellini P, Hummelshoj L, Rubin S, Goverde AJ, De Leo V, Petraglia F. Sex steroid hormones and reproductive disorders: impact on women's health. *Reprod Sci* 2011; **18**: 702-712 [PMID: 21795737 DOI: 10.1177/1933719111405068]

72 **Frenkel B**, Hong A, Baniwal SK, Coetzee GA, Ohlsson C, Khalid O, Gabet Y. Regulation of adult bone turnover by sex steroids. *J Cell Physiol* 2010; **224**: 305-310 [PMID: 20432458 DOI: 10.1002/jcp.22159]

73 **Ashida K**, Akehi Y, Kudo T, Yanase T. [Bone and Men's Health. The role of androgens in bone metabolism]. *Clin Calcium* 2010; **20**: 165-173 [PMID: 20118507]

74 **Farquhar C**, Marjoribanks J, Lethaby A, Suckling JA, Lamberts Q. Long term hormone therapy for perimenopausal and postmenopausal women. *Cochrane Database Syst Rev* 2009; **(2)**: CD004143 [PMID: 19370593 DOI: 10.1002/14651858.CD004143.pub3]

75 **Driscoll I**, Resnick SM. Testosterone and cognition in normal aging and Alzheimer's disease: an update. *Curr Alzheimer Res* 2007; **4**: 33-45 [PMID: 17316164 DOI: 10.2174/156720507779939878]

76 **Hogervorst E**, Yaffe K, Richards M, Huppert FA. Hormone replacement therapy to maintain cognitive function in women with dementia. *Cochrane Database Syst Rev* 2009; **(1)**: CD003799 [PMID: 19160224 DOI: 10.1002/14651858.CD003799.pub2]

77 **Lethaby A**, Hogervorst E, Richards M, Yesufu A, Yaffe K. Hormone replacement therapy for cognitive function in postmenopausal women. *Cochrane Database Syst Rev* 2008; **(1)**: CD003122 [PMID: 18254016 DOI: 10.1002/14651858.CD003122.pub2]

78 **George S**, Petit GH, Gouras GK, Brundin P, Olsson R. Nonsteroidal selective androgen receptor modulators and selective estrogen receptor β agonists moderate cognitive deficits and amyloid-β levels in a mouse model of Alzheimer's disease. *ACS Chem Neurosci* 2013; **4**: 1537-1548 [PMID: 24020966 DOI: 10.1021/cn400133s]

79 **Gårevik N**, Skogastierna C, Rane A, Ekström L. Single dose testosterone increases total cholesterol levels and induces the expression of HMG CoA reductase. *Subst Abuse Treat Prev Policy* 2012; **7**: 12 [PMID: 22433938 DOI: 10.1186/1747-597X-7-12]

80 **Li S**, Liu B, Zhang L, Rong L. Amyloid beta peptide is elevated in osteoporotic bone tissues and enhances osteoclast function. *Bone* 2014; **61**: 164-175 [PMID: 24473375 DOI: 10.1016/j.bone.2014.01.010]

81 **Strubel D**, Jacquot JM, Martin-Hunyadi C. [Dementia and falls]. *Ann Readapt Med Phys* 2001; **44**: 4-12 [PMID: 11587649 DOI: 10.1016/S0168-6054(00)00057-X]

82 **Haasum Y**, Fastbom J, Fratiglioni L, Johnell K. Undertreatment of osteoporosis in persons with dementia? A population-based study. *Osteoporos Int* 2012; **23**: 1061-1068 [PMID: 21499775 DOI: 10.1007/s00198-011-1636-8]

83 **Switzer JA**, Jaglal S, Bogoch ER. Overcoming barriers to osteoporosis care in vulnerable elderly patients with hip fractures. *J Orthop Trauma* 2009; **23**: 454-459 [PMID: 19550234 DOI: 10.1097/BOT.0b013e31815e92d2]

84 **Amouzougan A**, Lafaie L, Marotte H, Dẻnariẻ D, Collet P, Pallot-Prades B, Thomas T. High prevalence of dementia in women with osteoporosis. *Joint Bone Spine* 2016 [PMID: 27697401]

85 **Mughal N**, Inderjeeth CA. Residential status decline and increased mortality - a consequence of under-treatment of osteoporosis in patients with dementia. Findings from an ortho-geriatric unit. *Australas J Ageing* 2015; **34** (SI-1): 57-58

86 **Chang KH**, Chung CJ, Lin CL, Sung FC, Wu TN, Kao CH. Increased risk of dementia in patients with osteoporosis: a population-based retrospective cohort analysis. *Age (Dordr)* 2014; **36**: 967-975 [PMID: 24347180 DOI: 10.1007/s11357-013-9608-x]

87 **Knopp-Sihota JA**, Cummings GG, Newburn-Cook CV, Homik J, Voaklander D. Dementia diagnosis and osteoporosis treatment propensity: a population-based nested case-control study. *Geriatr Gerontol Int* 2014; **14**: 121-129 [PMID: 23992035]

88 **Wilkins CH**, Sheline YI, Roe CM, Birge SJ, Morris JC. Vitamin D deficiency is associated with low mood and worse cognitive performance in older adults. *Am J Geriatr Psychiatry* 2006; **14**: 1032-1040 [PMID: 17138809 DOI: 10.1097/01.JGP.0000240986.74642.7c]

89 **Przybelski RJ**, Binkley NC. Is vitamin D important for preserving cognition? A positive correlation of serum 25-hydroxyvitamin D concentration with cognitive function. *Arch Biochem Biophys* 2007; **460**: 202-205 [PMID: 17258168 DOI: 10.1016/j.abb.2006.12.018]

90 **McGrath J**, Scragg R, Chant D, Eyles D, Burne T, Obradovic D. No association between serum 25-hydroxyvitamin D3 level and performance on psychometric tests in NHANES III. *Neuroepidemiology* 2007; **29**: 49-54 [PMID: 17898524 DOI: 10.1159/000108918]

91 **Oudshoorn C**, Mattace-Raso FU, van der Velde N, Colin EM, van der Cammen TJ. Higher serum vitamin D3 levels are associated with better cognitive test performance in patients with Alzheimer's disease. *Dement Geriatr Cogn Disord* 2008; **25**: 539-543 [PMID: 18503256 DOI: 10.1159/000134382]

92 **Annweiler C**, Schott AM, Rolland Y, Blain H, Herrmann FR, Beauchet O. Dietary intake of vitamin D and cognition in older women: a large population-based study. *Neurology* 2010; **75**: 1810-1816 [PMID: 21079183 DOI: 10.1212/WNL.0b013e3181fd6352]

93 **Rondanelli M**, Trotti R, Opizzi A, Solerte SB. Relationship among nutritional status, pro/antioxidant balance and cognitive performance in a group of free-living healthy elderly. *Minerva Med* 2007; **98**: 639-645 [PMID: 18299677]

94 **Jorde R**, Waterloo K, Saleh F, Haug E, Svartberg J. Neuropsychological function in relation to serum parathyroid hormone and serum 25-hydroxyvitamin D levels. The Tromsø study. *J Neurol* 2006; **253**: 464-470 [PMID: 16283099 DOI: 10.1007/s00415-005-0027-5]

95 **Slinin Y**, Paudel ML, Taylor BC, Fink HA, Ishani A, Canales MT, Yaffe K, Barrett-Connor E, Orwoll ES, Shikany JM, Leblanc ES, Cauley JA, Ensrud KE. 25-Hydroxyvitamin D levels and cognitive performance and decline in elderly men. *Neurology* 2010; **74**: 33-41 [PMID: 19940271 DOI: 10.1212/WNL.0b013e3181c7197b]

96 **Przybelski R**, Agrawal S, Krueger D, Engelke JA, Walbrun F, Binkley N. Rapid correction of low vitamin D status in nursing home residents. *Osteoporos Int* 2008; **19**: 1621-1628 [PMID: 18421544 DOI: 10.1007/s00198-008-0619-x]

**P-Reviewer:** Gonzalez-Reimers E, Lee YK, Li JX **S-Editor:** Ji FF **L-Editor: E-Editor:**

**Table 1 Studies investigating the association between vitamin D and cognition**

|  |  |  |  |
| --- | --- | --- | --- |
| **Study design** | **Ref.** | **Population** | **Results** |
| Cross-sectional study | [[88](#_ENREF_84)] | 80 community-dwelling women40 with mild AD40 cognitively-intact | Vitamin D deficiency was associated with impairment on two of four measures of cognitive performance |
|  | [[89](#_ENREF_85)] | 32 community-dwelling patients | Significant positive correlation between vitamin D concentrations and MMSE scores |
|  | [90] | 9556 community-dwelling patients | Lower 25(OH)D levels were not associated with impaired performance on various psychometric measures |
|  | [91] | 225 older outpatients diagnosed as having probable AD | Significant positive association between MMSE test scores and serum 25-hydroxyvitamin D(3) levels |
|  | [92] | 5596 community-dwelling women | Significant positive association between vitamin D intakes and cognitive performance. |
|  | [[9](#_ENREF_89)3] | 69 community-dwelling patients | A significant negative correlation between dietary intake of vitamin D and poor performance on cognitive tests |
| Case-control study | [[94](#_ENREF_90)] | 148 community-dwelling patients | No significant positive association between cognitive performance and serum 25-hydroxyvitamin D(3) levels |
| Longitudinal study | [[95](#_ENREF_91)] | 1138 community-dwelling men | Independent association between lower vitamin D levels and odds of cognitive decline |
|  | [[19](#_ENREF_19)] | 175 community-dwelling patients | 1.60-fold risk of losing at least 3 points on MMSE in 6 yr with low baseline vitamin D |
| Pre-post study | [[96](#_ENREF_92)] | 63 frail nursing home residents25 in intervention group38 in control group | No treatment-induced improvement in ambulation, cognition or behaviour was observed |
|  | [[21](#_ENREF_21)] | 13 community-dwelling patients with mild to moderate AD | Significant improvement in ADAs-cog score |
| Randomised controlled trial | [[21](#_ENREF_21)] | 32 community-dwelling patients with mild to moderate AD16 in intervention group16 in control group | Neither cognition nor disability changed significantly after high-dose D |

AD: Alzheimer’s disease.